268 related articles for article (PubMed ID: 35403875)
1. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
Tan H; Li X; Li Y; He F; ZhangBao J; Zhou L; Yang L; Zhao C; Lu C; Dong Q; Li H; Quan C
Front Immunol; 2024; 15():1343531. PubMed ID: 38558796
[TBL] [Abstract][Full Text] [Related]
4. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
5. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
9. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
11. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
12. Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
Lorefice L; Pilotto S; Fenu G; Cimino P; Firinu D; Frau J; Murgia F; Coghe G; Cocco E
J Neurol Sci; 2022 Jul; 438():120292. PubMed ID: 35605316
[TBL] [Abstract][Full Text] [Related]
13. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
[TBL] [Abstract][Full Text] [Related]
15. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of ozanimod
Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M
Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023
[TBL] [Abstract][Full Text] [Related]
17. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
18. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
Hillert J; Tsai JA; Nouhi M; Glaser A; Spelman T
Mult Scler; 2022 Feb; 28(2):237-246. PubMed ID: 34080926
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
Mukhtar H; Yasmeen U; Siddiqa S; Sarfraz Z; Sarfraz A
Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
